All Articles

Divergent transcriptional programs and constrained metabolic states reveal selective metabolic dependencies in chemoresistant luminal breast cancer

Adenylosuccinate lyase in pancreatic ductal adenocarcinoma chemoresistance: from purine metabolism to metabolic vulnerability

Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosis

Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity

Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment

Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells

DNA damage and metabolic mechanisms of cancer drug resistance

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer

P53-regulated autophagy and its impact on drug resistance and cell fate

Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance

PHGDH as a mechanism for resistance in metabolically-driven cancers

Drug resistance in glioblastoma: are persisters the key to therapy?

Glioblastoma chemoresistance: roles of the mitochondrial melatonergic pathway

Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem

Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts